<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36909731</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.</ArticleTitle><Pagination><StartPage>1097809</StartPage><MedlinePgn>1097809</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1097809</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2023.1097809</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.</AbstractText><AbstractText Label="METHODS">Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.8 months [range, 15.2-19.5 months]). All patients were functionally autonomous with regard to daily living (Barthel index: 100) and had normal physical examinations.</AbstractText><AbstractText Label="RESULTS">From the APLICOV-PC date of discharge to the date of the extension visit, neither Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade 3-4 complications nor QT prolongation or significant electrocardiogram (EKG) abnormalities were reported. Five (14.7%) patients had another COVID-19 episode after initial discharge from APLICOV-PC, and in 2 patients (5.9%), previously unreported chest X-ray findings were documented. Spirometry and lung-diffusion tests were normal in 29 (85.3%) and 27 (79.4%) patients, respectively, and 3 patients needed additional oxygen supplementation after initial hospital discharge. None of these patients required subsequent hospital readmission for disease-related complications.</AbstractText><AbstractText Label="DISCUSSION">In conclusion, plitidepsin has demonstrated a favorable long-term safety profile in adult patients hospitalized for COVID-19. With the constraints of a low sample size and a lack of control, the rate of post-COVID-19 complications after treatment with plitidepsin is in the low range of published reports. (ClinicalTrials.gov Identifier: NCT05121740; https://clinicaltrials.gov/ct2/show/NCT05121740).</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Varona, Landete, Paredes, Vates, Torralba, Guisado-Vasco, Porras, Mu&#xf1;oz, Gijon, Ancochea, Saiz, Meira, Jimeno, Lopez-Martin and Estrada.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varona</LastName><ForeName>Jose F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Hospital Universitario HM Monteprincipe, HM Hospitales, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad San Pablo-Centro de Estudios Universitarios (CEU), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landete</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Neumolog&#xed;a, Hospital Universitario La Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, IrsiCaixa Acquired Immunodeficiency Syndrome (AIDS) Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Enfermedades Infecciosas Hospital Germans Trias I Pujol, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vates</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital Universitario de Getafe, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torralba</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine Department, Health Sciences Faculty, University of Alcal&#xe1;, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Guadalajara University Hospital, Guadalajara, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guisado-Vasco</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Medicina, Facultad de Ciencias Biom&#xe9;dicas y de la Salud, Universidad Europea, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hospital General de Ciudad Real, Ciudad Real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Microbiology and Infectious Diseases Department, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijon</LastName><ForeName>Paloma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Microbiology and Infectious Diseases Department, Instituto de Investigaci&#xf3;n Sanitaria Gregorio Mara&#xf1;&#xf3;n (IiSGM), Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancochea</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Neumolog&#xed;a, Hospital Universitario La Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiz</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Virology Unit, PharmaMar, SA, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meira</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Virology Unit, PharmaMar, SA, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimeno</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Virology Unit, PharmaMar, SA, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Martin</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Virology Unit, PharmaMar, SA, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna Hospital Cl&#xed;nico San Carlos, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05121740</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Y76ID234HW</RegistryNumber><NameOfSubstance UI="C098980">plitidepsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">plitidepsin</Keyword><Keyword MajorTopicYN="N">post-COVID-19 complications</Keyword></KeywordList><CoiStatement>VE has received personal fees from Janssen, Gilead, and ViiV and grants from MSD. RP has participated in Advisory Boards from Gilead, MSD, ViiV Healthcare, and Theratechnologies. MT has received consulting fees as a member of Advisory Committee and honoraria and speaking fees from Gilead, Janssen, MSD, and ViiV Companies. PG-V received speaker fees from FLS Science, Pharma Mar SA Madrid, Spain and GlaxoSmithKline Spain; consulting fees from Angelini Pharma and Pharma Mar SA; served as an advisory board member for Berlin Cures GmbH and Pharma Mar SA; and meeting grants from GlaxoSmithKline and Pharma Mar SA. JJ holds stocks of Pangaea Oncology, has a non-remunerated role in the Scientific Advisory Board and holds stocks of Promontory Therapeutics, and is a full-time employee of Pharmamar, SA Madrid, Spain and owns stocks. JL-M is a full-time employee and shareholder of Pharmamar, SA Madrid, Spain. ES and FM are full-time employees of Pharmamar, SA Madrid, Spain. JL-M is a co-inventor of a patent for plitidepsin WO2008135793A1. JJ is a co-inventor on a patent for didemnin WO99/42125 and on patents for aplidine WO03/033013 and WO 2004/080421. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36909731</ArticleId><ArticleId IdType="pmc">PMC9992643</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2023.1097809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aggarwal G., Cheruiyot I., Aggarwal S., Wong J., Lippi G., Lavie C. J., et al. . (2020). Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: A meta-analysis. Curr. Probl Cardiol. 45 (8), 100617. doi:&#xa0;10.1016/j.cpcardiol.2020.100617</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100617</ArticleId><ArticleId IdType="pmc">PMC7187816</ArticleId><ArticleId IdType="pubmed">32402515</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., et al. . (2021). Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg. Health Eur. 6, 100122. doi:&#xa0;10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Babapoor-Farrokhran S., Gill D., Walker J., Rasekhi R. T., Bozorgnia B., Amanullah A. (2020). Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 253, 117723. doi:&#xa0;10.1016/j.lfs.2020.117723</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117723</ArticleId><ArticleId IdType="pmc">PMC7194533</ArticleId><ArticleId IdType="pubmed">32360126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. (2020). Cardiovascular disease and COVID-19. Diabetes Metab. Syndr. 14 (3), 247&#x2013;250. doi:&#xa0;10.1016/j.dsx.2020.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt-Due A., Olsen I. C., Nezvalova-Henriksen K., K&#xe5;sine T., Lund-Johansen F., Hoel H., et al. . (2021). Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: A randomized trial. Ann. Intern. Med. 174 (9), 1261&#x2013;1269. doi:&#xa0;10.7326/M21-0653</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-0653</ArticleId><ArticleId IdType="pmc">PMC8279143</ArticleId><ArticleId IdType="pubmed">34251903</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Piazza M., Boner A. L., Bellanti J. A. (2022). Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc. 43 (3), 187&#x2013;193. doi:&#xa0;10.2500/aap.2022.43.220018</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/aap.2022.43.220018</ArticleId><ArticleId IdType="pmc">PMC9106095</ArticleId><ArticleId IdType="pubmed">35524358</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. (2020). Gemelli against COVID-19 post-acute care study group. persistent symptoms in patients after acute COVID-19. JAMA. 324 (6), 603&#x2013;605. doi:&#xa0;10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin K. J., Fried J. A., Raikhelkar J., Sayer G., Griffin J. M., Masoumi A., et al. . (2020). COVID-19 and cardiovascular disease. Circulation. 141 (20), 1648&#x2013;1655. doi:&#xa0;10.1161/CIRCULATIONAHA.120.046941</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046941</ArticleId><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri L., Moss S., Khan F. A., Chi W., Xia J., Robinson K., et al. . (2022). Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: A systematic review and meta-analysis. Thorax 78(2), 191&#x2013;201. doi:&#xa0;10.1136/thoraxjnl-2021-218275</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-218275</ArticleId><ArticleId IdType="pubmed">35338102</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham E. L., Clark J. R., Orban Z. S., Lim P. H., Szymanski A. L., Taylor C., et al. . (2021). Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized covid-19 &#x201c;long haulers&#x201d;. Ann. Clin. Transl. Neurol. 8 (5), 1073&#x2013;1085. doi:&#xa0;10.1002/acn3.51350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. (2020). Management of post-acute covid-19 in primary care. BMJ 370, m3026. doi:&#xa0;10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. . (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 397 (10270), 220&#x2013;232. doi:&#xa0;10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc H. C., Xiao J., Liu W., Li Y., Chen G. (2022). Long COVID and its management. Int. J. Biol. Sci. 18 (12), 4768&#x2013;4780. doi:&#xa0;10.7150/ijbs.75056</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Park S. S., Kim T. Y., Lee D. G., Kim D. W. (2021). Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study. Cancers 13 (3), 471. doi:&#xa0;10.3390/cancers13030471</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13030471</ArticleId><ArticleId IdType="pmc">PMC7865511</ArticleId><ArticleId IdType="pubmed">33530509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P. A., Cuapio A., et al. . (2021). More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 11, 16144. doi:&#xa0;10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Machhi J., Herskovitz J., Senan A. M., Dutta D., Nath B., Oleynikov M. D., et al. . (2020). The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 15 (3), 359&#x2013;386. doi:&#xa0;10.1007/s11481-020-09944-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-020-09944-5</ArticleId><ArticleId IdType="pmc">PMC7373339</ArticleId><ArticleId IdType="pubmed">32696264</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and Care Excellence  (2020) COVID-19 rapid guideline: Managing the long-term effects of COVID-19. Available at: https://www.nice.org.uk/guidance/ng188 (Accessed October 2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and Care Research  (2020) Living with Covid19. Available at: https://evidence.nihr.ac.uk/themedreview/living-with-covid19/ (Accessed October 2022).</Citation></Reference><Reference><Citation>Ojha V., Mani A., Pandey N. N., Sharma S., Kumar S. (2020). CT in coronavirus disease 2019 (COVID-19): A systematic review of chest CT findings in 4410 adult patients. Eur. Radiol. 30 (11), 6129&#x2013;6138. doi:&#xa0;10.1007/s00330-020-06975-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-06975-7</ArticleId><ArticleId IdType="pmc">PMC7261039</ArticleId><ArticleId IdType="pubmed">32474632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan S., Khunti K., Alwan N., Steves C., MacDermott N., Morsella A., et al. . (2021). In the wake of the pandemic: Preparing for long COVID (Copenhagen (Denmark: European Observatory on Health Systems and Policies; ).</Citation><ArticleIdList><ArticleId IdType="pubmed">33877759</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi S., Reddy S., Gholamrezanezhad A. (2020). Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): What we know and what to expect. J. Thorac. Imaging 35 (4), W87&#x2013;W89. doi:&#xa0;10.1097/RTI.0000000000000534</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RTI.0000000000000534</ArticleId><ArticleId IdType="pubmed">32404798</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh T., Kite T. A., Joshi S. S., Spath N. B., Kershaw L., Baker A., et al. . (2022). MRI And CT coronary angiography in survivors of COVID-19. Heart. 108 (1), 46&#x2013;53. doi:&#xa0;10.1136/heartjnl-2021-319926</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319926</ArticleId><ArticleId IdType="pmc">PMC8503921</ArticleId><ArticleId IdType="pubmed">34615668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C. H., Murray B., Varsavsky T., Graham M. S., Penfold R. S., Bowyer R. C., et al. . (2021). Attributes and predictors of long COVID. Nat. Med. 27 (4), 626&#x2013;631. doi:&#xa0;10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J. R., Husain M., Luciano S., Harrison P. J. (2021). 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8 (5), 416&#x2013;427. doi:&#xa0;10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Varona J. F., Landete P., Lopez-Martin J. A., Estrada V., Paredes R., Guisado-Vasco P., et al. . (2022). Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci. Alliance 5 (4), e202101200. doi:&#xa0;10.26508/lsa.202101200</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202101200</ArticleId><ArticleId IdType="pmc">PMC8761492</ArticleId><ArticleId IdType="pubmed">35012962</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N., Benros M. E. (2020). COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav. Immun. 89, 531&#x2013;542. doi:&#xa0;10.1016/j.bbi.2020.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7260522</ArticleId><ArticleId IdType="pubmed">32485289</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization  (2022) Weekly epidemiological and operational updates October 2022. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (Accessed October 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>